China Punishes Hospital, Govt Heads For Med Overpricing, Funding Misuse
This article was originally published in PharmAsia News
Executive Summary
China's National Audit Office said it had rectified drug overprices of 23 hospitals in 17 counties totaling RMB 66.77 million ($10.73 million), publicized the corrected prices, and punished nine held responsible verbally and administratively.
You may also be interested in...
European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
QUOTED. 2 March 2021. Michael Coyle.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Drug Manufacturers Beg US FDA To Inspect Facilities, But Still Find Difficulties
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.
Need a specific report? 1000+ reports available
Buy Reports